Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Orbisresearch.com published “Non-alcoholic Steatohepatitis (NASH) Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, January 05, 2019 ) Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Key Highlights:
- Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
- Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
- Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time.
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2435821
Scope:
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy:
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2435821
Key Players:
• Afimmune
• Akarna Therapeutics
• Akero Therapeutics
• Albireo
• Allergan
• Allergan (acquired from
• Ardelyx
• Arisaph
• AstraZeneca
• BHV Pharma Inc
• Bird Rock Bio/Janssen
• BMS
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Cempra
• Cerenis Therapeutics
• ChemomAb
• Cirius Therapeutics
• CohBar
• ConSynance Therapeutics
• CymaBay Therapeutics
• DeuteRx
• Dr. Falk Pharma GmbH
• DURECT Corporation
• Eli Lilly
• Enanta
• Galectin Therapeutics
• Galmed
• Gemcabene
• Genfit
• Gilead
• GRI Bio
• HighTide Biopharma
• Immune Pharmaceuticals Inc.
• Immuron
• Intercept
• INVENT Pharmaceuticals
• Inventiva
• Ionis Pharma-ceuticals
• Janssen
• Madrigal
• MediciNova
• Metacrine
• Mitsubishi Tanabe
• Naia
• NGM Biopharmaceuticals
• Nitto Denko
• NorthSea Therapeutics
• Novartis
• Novo Nordisk
• NuSirt BioPharma
• Oramed
• Pfizer
• Poxel
• Sanofi
• Second Genome
• Shire
• Sinew Pharma
• Sucampo Pharmaceuticals
• Synairgen
• Taiwan Pharmaceuticals
• Teva
• Tiziana Life Sciences
• Valbiotis
• Viking Therapeutics
• Virobay
• Zafgen
• Zydus Discovery
Key Points from TOC:
Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Appendix
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/competitor-landscape-non-alcoholic-steatohepatitis-nash
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Key Highlights:
- Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
- Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
- Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time.
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2435821
Scope:
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy:
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2435821
Key Players:
• Afimmune
• Akarna Therapeutics
• Akero Therapeutics
• Albireo
• Allergan
• Allergan (acquired from
• Ardelyx
• Arisaph
• AstraZeneca
• BHV Pharma Inc
• Bird Rock Bio/Janssen
• BMS
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Cempra
• Cerenis Therapeutics
• ChemomAb
• Cirius Therapeutics
• CohBar
• ConSynance Therapeutics
• CymaBay Therapeutics
• DeuteRx
• Dr. Falk Pharma GmbH
• DURECT Corporation
• Eli Lilly
• Enanta
• Galectin Therapeutics
• Galmed
• Gemcabene
• Genfit
• Gilead
• GRI Bio
• HighTide Biopharma
• Immune Pharmaceuticals Inc.
• Immuron
• Intercept
• INVENT Pharmaceuticals
• Inventiva
• Ionis Pharma-ceuticals
• Janssen
• Madrigal
• MediciNova
• Metacrine
• Mitsubishi Tanabe
• Naia
• NGM Biopharmaceuticals
• Nitto Denko
• NorthSea Therapeutics
• Novartis
• Novo Nordisk
• NuSirt BioPharma
• Oramed
• Pfizer
• Poxel
• Sanofi
• Second Genome
• Shire
• Sinew Pharma
• Sucampo Pharmaceuticals
• Synairgen
• Taiwan Pharmaceuticals
• Teva
• Tiziana Life Sciences
• Valbiotis
• Viking Therapeutics
• Virobay
• Zafgen
• Zydus Discovery
Key Points from TOC:
Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Appendix
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/competitor-landscape-non-alcoholic-steatohepatitis-nash
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results